ISSN: 0145-2126

Journal Home

Journal Guideline

Leukemia Research Q2 Unclaimed

Elsevier Ltd United Kingdom

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Leukemia Research is a journal indexed in SJR in Hematology and Oncology with an H index of 98. It has an SJR impact factor of 0,784 and it has a best quartile of Q2. It is published in English. It has an SJR impact factor of 0,784.

Leukemia Research focuses its scope in these topics and keywords: leukemia, antibody, induces, monoclonal, myeloid, anticd, apoptosis, band, cells, chronic, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy:

Type of publications:

Publication frecuency: -

Categories: Hematology (Q2) Oncology (Q2) Cancer Research (Q3)

Price

- €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

0,784

SJR Impact factor

98

H Index

104

Total Docs (Last Year)

412

Total Docs (3 years)

3865

Total Refs

657

Total Cites (3 years)

303

Citable Docs (3 years)

1.62

Cites/Doc (2 years)

37.16

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Thrombosis Research Q2
Cancer Control Q2
Annals of Hematology Q2
Platelets Q2
Transfusion Medicine Reviews Q2

Compare this journals

Aims and Scope

Best articles by citations

Younger age observation IN myelodysplastic syndrome

Translocation (8;21) in acute myeloid leukemia: When to treat? That is the question!!

p53 overexpression in bone marrow biopsies in refractory anemia and aplastic anemia: impact of antibody selection

Sezary cells with hairy projections

121 Myelodysplastic syndrome and 17P deletion

A comparison of the effect of bcr/abl breakpoint specific phosphothiorate oligodeoxynucleotides on colony formation by bcr/abl positive and negative, CD34 enriched mononuclear cell populations

76 The absolute number of CD34+ cells and CD34+ cells in S-phase increase during the evolution of myelodysplastic syndromes (MDS)

125 Clonal karyotypic abnormalities after autologous transplantation (AT)

163 Amifostine in low-risk and combined therapy with gemcitabine in high-risk myelodysplastic syndromes

50 Correlation of karyotype with clinical features and prognosis in 349 patients with MDS

127 Both inhaled and ingested substances are involved in secondary myelodysplastic syndromes (MDS) with 6p changes

128 Single del(11q) in a patient with RAEB which progressed to erythroleukemia

SHOW MORE ARTICLES

169 Aggressive chemotherapy in MDS: The Dusseldorf experience

26 Cytoplasmic abnormalities of erythroblasts in a patient with refractory anaemia with ring sideroblasts

8 The history of MDS: The role of the F.A.B. classification and the development of risk assessment

Deletion of parental GST genes as a possible susceptibility factor in the etiology of infant leukemia

Tobacco, alcohol, diet and risk of non-Hodgkin's lymphoma: a case-control study in Uruguay

KRN5500 induces apoptosis (PCD) of myeloid leukemia cell lines and patient blasts

The MRD1 (P-glycoprotein) and MRP (P-190) transporters do not play a major role in the intrinsic multiple drug resistance of Jurkat T lymphocytes

Autocrine and possible intracrine regulation of HL-60 cell proliferation by macrophage colony-stimulating factor

45 Myelodysplastic syndrome in its fibrotic variant: A borderline to chronic myeloproliferation

Successful management and perinatal outcome of pregnancy complicated with myelodysplastic syndrome

Autocrine NGFbeta/TRKA signalling is an important survival factor for Hodgkin lymphoma derived cell lines

132 A case of a t(1;3)(p36:q21) in chronic myelomonocytic leukemia with thrombocytosis and TPO gene expression in malignant cells